Novabay Pharmaceuticals (NBY)
NYSE MKT:NBY
Holding NBY?
Track your performance easily

NovaBay Pharma (NBY) Income Statement

637 Followers

NovaBay Pharma Income Statement

Last quarter (Q3 2024), NovaBay Pharma's total revenue was $2.44M, a decrease of -25.24% from the same quarter last year. In Q3, NovaBay Pharma's net income was $-1.21M. See NovaBay Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 11.20M$ 14.73M$ 14.40M$ 10.20M$ 9.93M$ 6.60M
Cost of Revenue
$ 4.41M$ 6.83M$ 6.62M$ 3.69M$ 3.97M$ 1.74M
Gross Profit
$ 6.79M$ 7.89M$ 7.78M$ 6.51M$ 5.96M$ 4.86M
Operating Expense
$ 12.14M$ 12.90M$ 15.46M$ 15.38M$ 12.39M$ 14.26M
Operating Income
$ -7.94M$ -7.60M$ -14.42M$ -8.86M$ -6.43M$ -9.40M
Net Non Operating Interest Income Expense
-----$ -18.00K
Other Income Expense
$ -4.69M$ -4.64M$ -2.93M$ -3.04M$ 4.61M$ 281.00K
Pretax Income
$ -11.36M$ -9.64M$ -10.61M$ -5.82M$ -11.03M$ -9.65M
Tax Provision
----$ 5.00K$ 6.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -15.56M$ -16.70M$ -16.27M$ -6.56M$ -11.04M$ -10.49M
Basic EPS
$ -3.59$ -3.96$ -10.10$ -5.25$ -10.85$ -16.80
Diluted EPS
$ -3.59$ -3.96$ -10.10$ -5.25$ -10.85$ -16.80
Basic Average Shares
$ 36.49M$ 4.21M$ 1.61M$ 1.25M$ 1.00M$ 618.31K
Diluted Average Shares
$ 36.49M$ 4.21M$ 1.61M$ 1.25M$ 1.00M$ 618.31K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 19.14M$ 19.73M$ 22.08M$ 19.07M$ 16.36M$ 16.00M
Net Income From Continuing And Discontinued Operation
$ -10.12M$ -9.64M$ -10.61M$ -6.56M$ -11.04M$ -9.66M
Normalized Income
$ -7.61M$ -8.30M-$ -4.60M--
Interest Expense
------
EBIT
$ -6.81M$ -5.00M$ -7.68M$ -8.86M$ -6.43M$ -9.63M
EBITDA
$ -5.60M$ -4.80M$ -7.20M$ -8.74M$ -6.38M$ -8.90M
Currency in USD

NovaBay Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis